Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Net Cash Flow (2019 - 2025)

Historic Net Cash Flow for BridgeBio Pharma (BBIO) over the last 7 years, with Q3 2025 value amounting to -$106.0 million.

  • BridgeBio Pharma's Net Cash Flow rose 2515.59% to -$106.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $237.2 million, marking a year-over-year increase of 30403.56%. This contributed to the annual value of $288.5 million for FY2024, which is 140241.96% up from last year.
  • BridgeBio Pharma's Net Cash Flow amounted to -$106.0 million in Q3 2025, which was up 2515.59% from $208.4 million recorded in Q2 2025.
  • BridgeBio Pharma's Net Cash Flow's 5-year high stood at $275.4 million during Q4 2024, with a 5-year trough of -$198.0 million in Q3 2021.
  • In the last 5 years, BridgeBio Pharma's Net Cash Flow had a median value of $13.1 million in 2022 and averaged $15.1 million.
  • As far as peak fluctuations go, BridgeBio Pharma's Net Cash Flow surged by 254818.64% in 2021, and later crashed by 26976.22% in 2025.
  • Over the past 5 years, BridgeBio Pharma's Net Cash Flow (Quarter) stood at $213.3 million in 2021, then crashed by 132.3% to -$68.9 million in 2022, then plummeted by 87.82% to -$129.4 million in 2023, then surged by 312.79% to $275.4 million in 2024, then crashed by 138.5% to -$106.0 million in 2025.
  • Its Net Cash Flow stands at -$106.0 million for Q3 2025, versus $208.4 million for Q2 2025 and -$140.5 million for Q1 2025.